138 related articles for article (PubMed ID: 26039609)
1. Ovarian protection during adjuvant chemotherapy.
Moore HC; Unger JM; Albain KS
N Engl J Med; 2015 Jun; 372(23):2269-70. PubMed ID: 26039609
[No Abstract] [Full Text] [Related]
2. Ovarian protection during adjuvant chemotherapy.
Oktay K; Rodriguez-Wallberg K; Munster P
N Engl J Med; 2015 Jun; 372(23):2268-9. PubMed ID: 26039611
[No Abstract] [Full Text] [Related]
3. Ovarian protection during adjuvant chemotherapy.
Peccatori FA
N Engl J Med; 2015 Jun; 372(23):2268. PubMed ID: 26039610
[No Abstract] [Full Text] [Related]
4. Goserelin reduces ovarian failure associated with breast cancer chemotherapy, study shows.
Mayor S
BMJ; 2015 Mar; 350():h1274. PubMed ID: 25752307
[No Abstract] [Full Text] [Related]
5. Breast cancer: Shielding the ovaries from chemotherapy in breast cancer.
Hutchinson L
Nat Rev Clin Oncol; 2015 May; 12(5):252. PubMed ID: 25801817
[No Abstract] [Full Text] [Related]
6. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
Moore HC; Unger JM; Phillips KA; Boyle F; Hitre E; Porter D; Francis PA; Goldstein LJ; Gomez HL; Vallejos CS; Partridge AH; Dakhil SR; Garcia AA; Gralow J; Lombard JM; Forbes JF; Martino S; Barlow WE; Fabian CJ; Minasian L; Meyskens FL; Gelber RD; Hortobagyi GN; Albain KS;
N Engl J Med; 2015 Mar; 372(10):923-32. PubMed ID: 25738668
[TBL] [Abstract][Full Text] [Related]
7. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial.
Leonard RCF; Adamson DJA; Bertelli G; Mansi J; Yellowlees A; Dunlop J; Thomas GA; Coleman RE; Anderson RA;
Ann Oncol; 2017 Aug; 28(8):1811-1816. PubMed ID: 28472240
[TBL] [Abstract][Full Text] [Related]
8. Ovarian function preservation with GnRH agonist in young breast cancer patients: does it impede the effect of adjuvant chemotherapy?
Kim J; Kim M; Lee JH; Lee H; Lee SK; Bae SY; Jun SY; Kil WH; Lee JE; Kim SW; Nam SJ
Breast; 2014 Oct; 23(5):670-5. PubMed ID: 25088482
[TBL] [Abstract][Full Text] [Related]
9. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC).
Urruticoechea A; Arnedos M; Walsh G; Dowsett M; Smith IE
Breast Cancer Res Treat; 2008 Aug; 110(3):411-6. PubMed ID: 17851753
[TBL] [Abstract][Full Text] [Related]
10. Questioning GnRH analogs for gonadal protection in cancer patients.
Oktay K; Sönmezer M
Fertil Steril; 2009 Aug; 92(2):e32; author reply e34. PubMed ID: 19646599
[No Abstract] [Full Text] [Related]
11. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
Del Mastro L; Boni L; Michelotti A; Gamucci T; Olmeo N; Gori S; Giordano M; Garrone O; Pronzato P; Bighin C; Levaggi A; Giraudi S; Cresti N; Magnolfi E; Scotto T; Vecchio C; Venturini M
JAMA; 2011 Jul; 306(3):269-76. PubMed ID: 21771987
[TBL] [Abstract][Full Text] [Related]
12. Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis.
Senra JC; Roque M; Talim MCT; Reis FM; Tavares RLC
Ultrasound Obstet Gynecol; 2018 Jan; 51(1):77-86. PubMed ID: 29055060
[TBL] [Abstract][Full Text] [Related]
13. Use of goserelin in the treatment of breast cancer.
Rody A; Loibl S; von Minckwitz G; Kaufmann M
Expert Rev Anticancer Ther; 2005 Aug; 5(4):591-604. PubMed ID: 16111461
[TBL] [Abstract][Full Text] [Related]
14. [Adjuvant chemotherapy of premenopausal breast cancer with LH-RH analogue for ovarian protection--a case report].
Asaga S; Ando J; Arai T; Fujii H
Gan To Kagaku Ryoho; 2005 Jul; 32(7):1069-72. PubMed ID: 16044976
[TBL] [Abstract][Full Text] [Related]
15. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
[TBL] [Abstract][Full Text] [Related]
16. Failure of ovarian ablation with goserelin in a pre-menopausal breast cancer patient resulting in pregnancy: a case report and review of the literature.
Hill N; Madarnas Y
Breast Cancer Res Treat; 2011 Aug; 129(1):265-8. PubMed ID: 21541703
[TBL] [Abstract][Full Text] [Related]
17. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
18. [LH-RH analogue for the treatment in premenopausal, receptor-positive breast cancer].
Sano M; Makino H
Nihon Rinsho; 2000 Apr; 58 Suppl():328-33. PubMed ID: 11026014
[No Abstract] [Full Text] [Related]
19. Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230.
Moore HCF; Unger JM; Phillips KA; Boyle F; Hitre E; Moseley A; Porter DJ; Francis PA; Goldstein LJ; Gomez HL; Vallejos CS; Partridge AH; Dakhil SR; Garcia AA; Gralow JR; Lombard JM; Forbes JF; Martino S; Barlow WE; Fabian CJ; Minasian LM; Meyskens FL; Gelber RD; Hortobagyi GN; Albain KS
J Natl Cancer Inst; 2019 Feb; 111(2):210-213. PubMed ID: 30371800
[TBL] [Abstract][Full Text] [Related]
20. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
; Cuzick J; Ambroisine L; Davidson N; Jakesz R; Kaufmann M; Regan M; Sainsbury R
Lancet; 2007 May; 369(9574):1711-23. PubMed ID: 17512856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]